Efficacy and safety of Cadonilimab plus anlotinib in small cell lung cancer with brain metastases
PurposeThis study aimed to evaluate the efficiency and safety of Cadonilimab and Anlotinib pairing in individuals diagnosed with small cell lung cancer (SCLC) and brain metastases (BMs).MethodsA review was performed on individuals who were diagnosed with small cell lung cancer (SCLC) and had central...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1545101/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849430529422655488 |
|---|---|
| author | Hai-Zhen Yi Wei Lv Jin-Jing Chen Zhan Lin |
| author_facet | Hai-Zhen Yi Wei Lv Jin-Jing Chen Zhan Lin |
| author_sort | Hai-Zhen Yi |
| collection | DOAJ |
| description | PurposeThis study aimed to evaluate the efficiency and safety of Cadonilimab and Anlotinib pairing in individuals diagnosed with small cell lung cancer (SCLC) and brain metastases (BMs).MethodsA review was performed on individuals who were diagnosed with small cell lung cancer (SCLC) and had central nervous system (CNS) metastases confirmed via magnetic resonance imaging (MRI) of the brain.We assessed the treatment response of Cadonilimab plus Anlotinib using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and Response assessment in neuro-oncology brain metastases (RANO-BM) for evaluating solid tumors and neuro-oncology brain metastases, respectively.The patients’ prognosis was determined using Kaplan-Meier analysis and Cox regression analysis.FindingsThe study initially included 46 patients diagnosed with SCLC who presented with brain metastases (BMs). According to the RANO-BM criteria, intracranial lesions showed an objective response rate (ORR) of 41.3%. The median overall survival (OS) was observed to be 19.3 months (95% CI, 17.4-21.1 months). Multivariate Cox regression analysis showed that having a PD1 level below 50% (HR=4.83, P <0.001) or having two or more metastatic organs (HR = 2.71, P = 0.036) were independent factors that positively predicted overall survival of all the patients, 86.9% experienced treatment-related adverse events (TRAEs) associated with the treatment, while 17.4% reported severe TRAEs of grade3-4.ImplicationsAccording to our results, the combination of Cadonilimab and Anlotinib appears to be a promising treatment option for SCLC patients with brain metastases. |
| format | Article |
| id | doaj-art-b538e05bb0f44e80898360c9201c8b06 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-b538e05bb0f44e80898360c9201c8b062025-08-20T03:27:57ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-07-011510.3389/fonc.2025.15451011545101Efficacy and safety of Cadonilimab plus anlotinib in small cell lung cancer with brain metastasesHai-Zhen Yi0Wei Lv1Jin-Jing Chen2Zhan Lin3Department of Medical Oncology, The First People’s Hospital of Yulin, Yulin, Guangxi, ChinaDepartment of Medical Center, The First People’s Hospital of Yulin, Yulin, Guangxi, ChinaDepartment of Medical Hematology, The First People's Hospital of Yulin, Yulin, Guangxi, ChinaDepartment of Medical Oncology, The First People’s Hospital of Yulin, Yulin, Guangxi, ChinaPurposeThis study aimed to evaluate the efficiency and safety of Cadonilimab and Anlotinib pairing in individuals diagnosed with small cell lung cancer (SCLC) and brain metastases (BMs).MethodsA review was performed on individuals who were diagnosed with small cell lung cancer (SCLC) and had central nervous system (CNS) metastases confirmed via magnetic resonance imaging (MRI) of the brain.We assessed the treatment response of Cadonilimab plus Anlotinib using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and Response assessment in neuro-oncology brain metastases (RANO-BM) for evaluating solid tumors and neuro-oncology brain metastases, respectively.The patients’ prognosis was determined using Kaplan-Meier analysis and Cox regression analysis.FindingsThe study initially included 46 patients diagnosed with SCLC who presented with brain metastases (BMs). According to the RANO-BM criteria, intracranial lesions showed an objective response rate (ORR) of 41.3%. The median overall survival (OS) was observed to be 19.3 months (95% CI, 17.4-21.1 months). Multivariate Cox regression analysis showed that having a PD1 level below 50% (HR=4.83, P <0.001) or having two or more metastatic organs (HR = 2.71, P = 0.036) were independent factors that positively predicted overall survival of all the patients, 86.9% experienced treatment-related adverse events (TRAEs) associated with the treatment, while 17.4% reported severe TRAEs of grade3-4.ImplicationsAccording to our results, the combination of Cadonilimab and Anlotinib appears to be a promising treatment option for SCLC patients with brain metastases.https://www.frontiersin.org/articles/10.3389/fonc.2025.1545101/fullsmall cell lung cancerCadonilimabbrain metastasesPD-1anlotinib |
| spellingShingle | Hai-Zhen Yi Wei Lv Jin-Jing Chen Zhan Lin Efficacy and safety of Cadonilimab plus anlotinib in small cell lung cancer with brain metastases Frontiers in Oncology small cell lung cancer Cadonilimab brain metastases PD-1 anlotinib |
| title | Efficacy and safety of Cadonilimab plus anlotinib in small cell lung cancer with brain metastases |
| title_full | Efficacy and safety of Cadonilimab plus anlotinib in small cell lung cancer with brain metastases |
| title_fullStr | Efficacy and safety of Cadonilimab plus anlotinib in small cell lung cancer with brain metastases |
| title_full_unstemmed | Efficacy and safety of Cadonilimab plus anlotinib in small cell lung cancer with brain metastases |
| title_short | Efficacy and safety of Cadonilimab plus anlotinib in small cell lung cancer with brain metastases |
| title_sort | efficacy and safety of cadonilimab plus anlotinib in small cell lung cancer with brain metastases |
| topic | small cell lung cancer Cadonilimab brain metastases PD-1 anlotinib |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1545101/full |
| work_keys_str_mv | AT haizhenyi efficacyandsafetyofcadonilimabplusanlotinibinsmallcelllungcancerwithbrainmetastases AT weilv efficacyandsafetyofcadonilimabplusanlotinibinsmallcelllungcancerwithbrainmetastases AT jinjingchen efficacyandsafetyofcadonilimabplusanlotinibinsmallcelllungcancerwithbrainmetastases AT zhanlin efficacyandsafetyofcadonilimabplusanlotinibinsmallcelllungcancerwithbrainmetastases |